Enzo Biochem Inc. [NYSE: ENZ] gained 6.25% on the last trading session, reaching $3.40 price per share at the time. The company report on June 10, 2021 that Enzo Biochem Reports Third Quarter Fiscal 2021 Results.
Total third quarter revenue of $32.8 million, a record quarterly high, increased 94% year-over-year.
Consolidated quarterly gross margin was 49% versus 26% in the previous year period, confirming Enzo’s vertically integrated approach can continue to drive healthy margins in a post pandemic environment.
Enzo Biochem Inc. represents 48.01 million in outstanding shares, while the company has a total market value of $170.34 million with the latest information. ENZ stock price has been found in the range of $3.2101 to $3.48.
If compared to the average trading volume of 1.24M shares, ENZ reached a trading volume of 1633538 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Enzo Biochem Inc. [ENZ]:
Rodman & Renshaw have made an estimate for Enzo Biochem Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on October 18, 2011. While these analysts kept the previous recommendation, Rodman & Renshaw raised their target price to Mkt Outperform. The new note on the price target was released on September 23, 2009, representing the official price target for Enzo Biochem Inc. stock. Previously, the target price had yet another raise to $19, while Lazard Capital analysts kept a Buy rating on ENZ stock.
The Average True Range (ATR) for Enzo Biochem Inc. is set at 0.16, with the Price to Sales ratio for ENZ stock in the period of the last 12 months amounting to 1.76. The Price to Book ratio for the last quarter was 2.64, with the Price to Cash per share for the same quarter was set at 0.89.
Trading performance analysis for ENZ stock
Enzo Biochem Inc. [ENZ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.59. With this latest performance, ENZ shares gained by 14.86% in over the last four-week period, additionally plugging by 41.08% over the last 6 months – not to mention a rise of 34.92% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ENZ stock in for the last two-week period is set at 64.32, with the RSI for the last a single of trading hit 71.23, and the three-weeks RSI is set at 59.52 for Enzo Biochem Inc. [ENZ]. The present Moving Average for the last 50 days of trading for this stock 3.18, while it was recorded at 3.19 for the last single week of trading, and 2.71 for the last 200 days.
Enzo Biochem Inc. [ENZ]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Enzo Biochem Inc. [ENZ] shares currently have an operating margin of -31.09 and a Gross Margin at +31.27. Enzo Biochem Inc.’s Net Margin is presently recorded at -37.52.
Return on Total Capital for ENZ is now -25.94, given the latest momentum, and Return on Invested Capital for the company is -33.48. Return on Equity for this stock declined to -39.50, with Return on Assets sitting at -26.02. When it comes to the capital structure of this company, Enzo Biochem Inc. [ENZ] has a Total Debt to Total Equity ratio set at 56.22. Additionally, ENZ Total Debt to Total Capital is recorded at 35.99, with Total Debt to Total Assets ending up at 29.16. Long-Term Debt to Equity for the company is recorded at 36.58, with the Long-Term Debt to Total Capital now at 23.42.
Reflecting on the efficiency of the workforce at the company, Enzo Biochem Inc. [ENZ] managed to generate an average of -$63,661 per employee. Receivables Turnover for the company is 7.65 with a Total Asset Turnover recorded at a value of 0.69.Enzo Biochem Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.30.
An analysis of insider ownership at Enzo Biochem Inc. [ENZ]
There are presently around $93 million, or 57.90% of ENZ stock, in the hands of institutional investors. The top three institutional holders of ENZ stocks are: HARBERT FUND ADVISORS, INC. with ownership of 5,175,913, which is approximately -7.913% of the company’s market cap and around 8.10% of the total institutional ownership; BLACKROCK INC., holding 3,908,254 shares of the stock with an approximate value of $13.29 million in ENZ stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $11.36 million in ENZ stock with ownership of nearly -6.056% of the company’s market capitalization.
Positions in Enzo Biochem Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 25 institutional holders increased their position in Enzo Biochem Inc. [NYSE:ENZ] by around 727,989 shares. Additionally, 44 investors decreased positions by around 2,580,896 shares, while 21 investors held positions by with 24,143,317 shares. The mentioned changes placed institutional holdings at 27,452,202 shares, according to the latest SEC report filing. ENZ stock had 8 new institutional investments in for a total of 169,732 shares, while 11 institutional investors sold positions of 378,945 shares during the same period.